Jin Medical International Ltd (ZJYL) FinancialsZJYLJin Medical International Ltd

Jin Medical International Ltd (ZJYL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Wheelchair, accounting for 72.9% of total sales, equivalent to $7.69M. Another important revenue stream is Wheelchair components and others. Understanding this composition is critical for investors evaluating how ZJYL navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

In the context of the broader market, ZJYL competes directly with industry leaders such as OBIO and MOBI. With a market capitalization of $340.91M, it holds a significant position in the sector. When comparing efficiency, ZJYL's gross margin of N/A stands against OBIO's 71.59% and MOBI's 83.21%. Such benchmarking helps identify whether Jin Medical International Ltd is trading at a premium or discount relative to its financial performance.

The stock has a very high P/E ratio of 147.30 and a price-to-sales ratio of 7.76, indicating potential overvaluation. The forward P/E is currently at 0, reflecting uncertainty in future earnings. The company has also experienced a significant decline in stock price, down 54.47% year-to-date and 67.17% over the past year.